CK Cell Technologies research and development company has established its new commercial arm, Endexome, to translate the research and development of its innovative regenerative medicine products into the clinic.
Endexome has a pipeline of therapeutic regenerative products in development. Human clinical pilot trials of Endexome’s human stem cell derived products have shown extremely promising results in patients.
Endexome is committed to developing and translating our discoveries from the lab to the clinic. We are looking for partnering opportunities.
To find out more, please contact Dr Daniella Goldberg daniella.g@ckcelltechnologies.com
